Effect of sacubitril/valsartan on cardiac filling pressures in patients with left ventricular systolic dysfunction

Sacubitril/valsartan is the newest neurohormonal agent approved for therapy in patients with heart failure with reduced ejection fraction (HFrEF). Little is known about its acute and incremental hemodynamic effects. We aimed to evaluate the change in hemodynamic profiles measured using an implanted monitoring device in HFrEF patients initiated on sacubitril/valsartan therapy.
Source: International Journal of Cardiology - Category: Cardiology Authors: Source Type: research